Main menu

Novel screening platform for highly muliplexed biomarker analysis


To date, most diagnostic tests rely upon the detection of a limited number of biomarkers. This often results in a lack of specificity to provide enough clinically useful detail on the pathology. To overcome this challenge, we developed a new strategy, which combines nanopore sequencing1,2 with barcoded nucleic acid probes, engineered to recognise a panel of biological targets (miRNAs, proteins, and small molecules). Our workflow is rapid, from sample preparation to results in 1 hour. The established method is easily adaptable, as the number and type of targets can be greatly expanded. Preliminary results indicate a significant advantage over existing techniques, which makes us believe that this approach could have an extensive impact on diagnostics and facilitate the transition to personalised medicine3.

Download the PDF

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag